Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 62, Issue 1, 39-47
Copyright © 2005 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berlana, D.
Right arrow Articles by Jódar, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berlana, D.
Right arrow Articles by Jódar, R.

Reports

Use of colistin in the treatment of multiple-drug-resistant gram-negative infections

David Berlana, J. M. Llop, E. Fort, M. B. Badia and R. Jódar

DAVID BERLANA, PHARM.D., is Hospital Pharmacy Specialist; J. M. LLOP, PH.D., PHARM.D., is Hospital Pharmacy Specialist; E. FORT, PHARM.D., is Hospital Pharmacy Specialist; M. B. BADIA, PHARM.D., is Hospital Pharmacy Specialist; and R. JÓDAR, PH.D., PHARM.D., is Hospital Pharmacy Specialist and Director of the Pharmacy Service; Pharmacy Service, Hospital Universitari de Bellvitge, Barcelona, Spain.

Address correspondence to Dr. Berlana at Servei de Farmacia, Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain (dberlana{at}hosppal.es).


Purpose. The use of colistin for the treatment of infections caused by multiple-drug-resistant (MDR) gram-negative micro-organisms was studied.

Methods. The efficacy of colistin for treating infections caused by MDR gram-negative microorganisms and the development of renal toxicity were studied in hospitalized adult patients in Spain. Patients treated between January 2001 and October 2001 were included.

Results. Over the study period, 71 courses of inhaled colistin, 12 courses of i.v. or intramuscular (i.m.) colistin, and 2 courses of intrathecal colistin were administered to 80 patients. All were infected by MDR organisms: 69 (86%) by Acinetobacter baumannii and 11 (14%) by Pseudomonas aeruginosa. In 41 patients (51%), the episodes were caused by A. baumannii strains susceptible exclusively to colistin. The causative organisms were cleared in 92% of the patients from whom posttreatment repeat specimens were obtained. The in-hospital mortality rate was 18% (14 patients). There were no significant changes in mean serum urea or creatinine concentrations in patients receiving i.v. or i.m. therapy.

Conclusion. Colistin was used in 80 patients infected with A. baumannii or P. aeruginosa and appeared to be efficacious and safe.

Index terms: Acinetobacter baumannii; Antibiotics; Bacterial infections; Colistin; Kidney diseases; Mortality; Pseudomonas aeruginosa; Resistance; Toxicity

 



This article has been cited by other articles:


Home page
Clin. Microbiol. Rev.Home page
D. Landman, C. Georgescu, D. A. Martin, and J. Quale
Polymyxins Revisited
Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
A. Y. Peleg, H. Seifert, and D. L. Paterson
Acinetobacter baumannii: Emergence of a Successful Pathogen
Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. S. Oliveira, G. V. B. Prado, S. F. Costa, R. S. Grinbaum, and A. S. Levin
Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
J. Antimicrob. Chemother., June 1, 2008; 61(6): 1369 - 1375.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
P. J. Bergen, J. Li, R. L. Nation, J. D. Turnidge, K. Coulthard, and R. W. Milne
Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model
J. Antimicrob. Chemother., March 1, 2008; 61(3): 636 - 642.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
E. Ioannidou, I. I. Siempos, and M. E. Falagas
Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1216 - 1226.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
T. M. Arnold, G. N. Forrest, and K. J. Messmer
Polymyxin antibiotics for gram-negative infections
Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 819 - 826.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
Z. He, D. Kisla, L. Zhang, C. Yuan, K. B. Green-Church, and A. E. Yousef
Isolation and Identification of a Paenibacillus polymyxa Strain That Coproduces a Novel Lantibiotic and Polymyxin
Appl. Envir. Microbiol., January 1, 2007; 73(1): 168 - 178.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J. Ng, I. B. Gosbell, J. A. Kelly, M. J. Boyle, and J. K. Ferguson
Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review
J. Antimicrob. Chemother., November 1, 2006; 58(5): 1078 - 1081.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
K. P Holloway, N. G Rouphael, J. B Wells, M. D King, and H. M Blumberg
Polymyxin B and Doxycycline Use in Patients with Multidrug-Resistant Acinetobacter baumannii Infections in the Intensive Care Unit
Ann. Pharmacother., November 1, 2006; 40(11): 1939 - 1945.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
M. B. Shirk, K. R. Donahue, and J. Shirvani
Unlabeled uses of nebulized medications.
Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1704 - 1716.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
P. J. Bergen, J. Li, C. R. Rayner, and R. L. Nation
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1953 - 1958.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
M. E. Falagas, S. K. Kasiakou, S. Tsiodras, and A. Michalopoulos
The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
Clin. Med. Res., June 1, 2006; 4(2): 138 - 146.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
J. Li, C. R. Rayner, R. L. Nation, R. Deans, R. Boots, N. Widdecombe, A. Douglas, and J. Lipman
Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration
Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4814 - 4815.
[Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
A. Katragkou and E. Roilides
Successful Treatment of Multidrug-Resistant Acinetobacter baumannii Central Nervous System Infections with Colistin
J. Clin. Microbiol., September 1, 2005; 43(9): 4916 - 4917.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society of Health-System Pharmacists.